Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

CAPS Rating: 4 out of 5

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.


Player Avatar TMFUltraLong (99.95) Submitted: 6/22/2010 1:27:10 PM : Underperform Start Price: $5.75 NBIX Score: +4.62

Neurocrine Biosciences, how you are still an operational entity is beyond my comprehension. NBIX has signed two deals over the last two days, with Abbott and a smaller deal with Boehringer to supply the company with much needed cash, 75M. The question of the day will be how many months will it take for them to burn through this 75M? My personally guess is on 16 months, but that's just me. Seriously, they should have left NBIX die when they had the chance. Trading at well over 10 times book even with the new cash infusion and over 100 times sales I really see no benefit to buying NBIX. Have you seen how far out the products are in their pipeline. Will we even see a phase III result before the end of 2012? Can they burn anything less than 50M dollars a year? If not they'll be out of cash before 2012 is over! Again, why didn't we let NBIX just die?UltraLong

Member Avatar briansal (42.22) Submitted: 7/29/2010 1:22:01 AM
Recs: 0

Wow! Harsh! I think you may lack some vision here.

Featured Broker Partners